

February 3, 2016

To Whom It May Concern

Company: Taisho Pharmaceutical Holdings Co., Ltd.
Representative: Akira Uehara, President and CEO
Stock code: 4581 (TSE First Section)
Contact: Takashi Shibata, General Manager
Corporate Communications
(Tel: +81-3-3985-1115)

Decision on Matters Concerning Stock Buyback
(Share acquisition based on the Articles of Incorporation
as stipulated by Article 165, Paragraph 2 of the Japanese Corporation Act)

Taisho Pharmaceutical Holdings Co., Ltd. has announced that its Board of Directors today passed a resolution to acquire its own shares, as detailed below. This acquisition is based on the provisions of Article 156 of the Japanese Corporation Act, which has been reinterpreted and applied in accordance with Article 165, Paragraph 3 of the same Act.

1. Reason for acquisition

The acquisition of the Company's own shares will facilitate flexible implementation of capital policy in response to changes in the business environment.

2. Details of acquisition

- (1) Type of stock: Taisho Pharmaceutical Holdings common stock
- (2) Amount of stock: 1,500,000 shares (upper limit)
(Percentage of total number of shares issued
-excluding treasury stock: 1.85%)
- (3) Total value of stock: ¥10,000 million (upper limit)
- (4) Period of acquisition: From February 9, 2016 to May 31, 2016

Notes: Treasury stock holdings as of January 31, 2016

Total number of shares issued (excluding treasury stock):	81,132,404 shares
Number of shares of treasury stock:	9,007,249 shares